GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1
Overview
Authors
Affiliations
Bromodomains are acetyllysine recognition domains present in a variety of human proteins. Bromodomains also bind small molecules that compete with acetyllysine, and therefore bromodomains have been targets for drug discovery efforts. Highly potent and selective ligands with good cellular permeability have been proposed as chemical probes for use in exploring the functions of many of the bromodomain proteins. We report here the discovery of a class of such inhibitors targeting the family VIII bromodomains of SMARCA2 (BRM) and SMARCA4 (BRG1), and PBRM1 (polybromo-1) bromodomain 5. We propose one example from this series, GNE-064, as a chemical probe for the bromodomains SMARCA2, SMARCA4, and PBRM1(5) with the potential for use.
Epigenetics-targeted drugs: current paradigms and future challenges.
Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S Signal Transduct Target Ther. 2024; 9(1):332.
PMID: 39592582 PMC: 11627502. DOI: 10.1038/s41392-024-02039-0.
Ordonez-Rubiano S, Maschinot C, Wang S, Sood S, Baracaldo-Lancheros L, Strohmier B J Med Chem. 2023; 66(16):11250-11270.
PMID: 37552884 PMC: 10641717. DOI: 10.1021/acs.jmedchem.3c00671.
The pyridazine heterocycle in molecular recognition and drug discovery.
Meanwell N Med Chem Res. 2023; :1-69.
PMID: 37362319 PMC: 10015555. DOI: 10.1007/s00044-023-03035-9.
Target 2035 - an update on private sector contributions.
Ackloo S, Antolin A, Bartolome J, Beck H, Bullock A, Betz U RSC Med Chem. 2023; 14(6):1002-1011.
PMID: 37360399 PMC: 10285765. DOI: 10.1039/d2md00441k.
Targeting Chromatin-Remodeling Factors in Cancer Cells: Promising Molecules in Cancer Therapy.
Zhang F, Li D Int J Mol Sci. 2022; 23(21).
PMID: 36361605 PMC: 9655648. DOI: 10.3390/ijms232112815.